ZAI LAB LIMITED Cash and Due from Banks
ZAI LAB LIMITED (ZLAB) had Cash and Due from Banks of $878.79 million as of 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Balance Sheet › Assets
us-gaap:CashAndDueFromBanks · last filed 2023-05-09
- 2023-03-31: Cash and Due from Banks $878.79M.
- 2022-12-31: Cash and Due from Banks $1.01B.
- 2022-09-30: Cash and Due from Banks $818.41M.
- 2022-06-30: Cash and Due from Banks $381.23M.
| Period end | Cash and Due from Banks | Cash and Due from Banks as first filed |
|---|---|---|
| 2023-03-31 | $878.79M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $1.01B 10-Q · filed 2023-05-09 | |
| 2022-09-30 | $818.41M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $381.23M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $547.26M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $663.47M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $1.10B 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $1.47B 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $1.01B 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $441.28M 10-K · filed 2022-03-01 | |
| 2020-06-30 | $257.77M 6-K · filed 2020-09-11 | |
| 2019-12-31 | $75.11M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $67.89M 6-K · filed 2020-01-21 | |
| 2018-12-31 | $36.78M 20-F · filed 2020-04-29 | $36.78M 20-F · filed 2019-03-29 |
| 2017-12-31 | $204.01M 20-F · filed 2019-03-29 | |
| 2016-12-31 | $36.53M 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |